Glucocorticosteroid Articles & Analysis

1 news found

EsoCap announces first patient enrolled in Phase II eosinophilic esophagitis trial

With our lead product, ESO-101, we now aim to provide long-lasting targeted topical delivery of the glucocorticosteroid mometasone furoate”, said Isabelle Racamier, EsoCap AG CEO. ...

Oct. 25, 2021

ByEsoCap AG

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you